Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated August 6, 2019, reports on the interim period ended June 30, 2019. The registrant, Aurinia Pharmaceuticals Inc., is a foreign private issuer headquartered in Victoria, British Columbia. The filing incorporates by reference the Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) for the second quarter of 2019.
Key Financial Metrics
The provided text serves as a cover sheet and exhibit index. It does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the attached exhibits (99.1 and 99.2) which are not included in the input text.
Material Changes
The filing text does not provide details on material changes versus the prior comparable period. Such analysis is contained within the MD&A (Exhibit 99.2) referenced in this report.
Guidance, Outlook, and Risks
No specific guidance, outlook, management commentary, risks, or contingencies are detailed in the cover document. The filing notes that the report is incorporated by reference into the Registration Statement on Form F-10 (File No. 333-222413).
Investor Verification Checklist
- Review Exhibit 99.1 for the actual Interim Condensed Consolidated Financial Statements to verify cash position and burn rate.
- Examine Exhibit 99.2 (MD&A) for clinical trial updates, regulatory milestones, and specific financial variances.
- Confirm the status of the Form F-10 Registration Statement (File No. 333-222413) referenced in the filing.
- Verify the certifications provided by the CEO and CFO in Exhibits 99.3 and 99.4.